Nasacort Aq is a drug owned by Sanofi Aventis Us Llc. It is protected by 3 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 03, 2016. Details of Nasacort Aq's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5976573 | Aqueous-based pharmaceutical composition |
Jul, 2016
(9 years ago) |
Expired
|
| US6143329 | Aqueous-based pharmaceutical composition |
Jul, 2016
(9 years ago) |
Expired
|
| US7977045 | Aqueous-based pharmaceutical composition |
Jul, 2016
(9 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Nasacort Aq's patents.
Latest Legal Activities on Nasacort Aq's Patents
Given below is the list of recent legal activities going on the following patents of Nasacort Aq.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent
Critical | 19 Aug, 2019 | US7977045 |
| Maintenance Fee Reminder Mailed
Critical | 04 Mar, 2019 | US7977045 |
| Patent Issue Date Used in PTA Calculation
Critical | 12 Jul, 2011 | US7977045 |
| Recordation of Patent Grant Mailed
Critical | 12 Jul, 2011 | US7977045 |
| Email Notification
Critical | 23 Jun, 2011 | US7977045 |
| Issue Notification Mailed
Critical | 22 Jun, 2011 | US7977045 |
| Application Is Considered Ready for Issue
Critical | 02 Jun, 2011 | US7977045 |
| Dispatch to FDC | 02 Jun, 2011 | US7977045 |
| Issue Fee Payment Verified
Critical | 01 Jun, 2011 | US7977045 |
| Issue Fee Payment Received
Critical | 01 Jun, 2011 | US7977045 |
FDA has granted several exclusivities to Nasacort Aq. Till the time
these exclusivities
are active, no other company can market a generic or bioequivalent version of Nasacort Aq, regardless of the status of it's patents. These exclusivities hence play a crucial role in
delaying the generic
launch. Given below are details of the exclusivities granted to
Nasacort Aq.
Exclusivity Information
Nasacort Aq holds 1 exclusivities. All of its exclusivities have expired in 2011. Details of Nasacort Aq's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Sep 19, 2011 |
US patents provide insights into the exclusivity only within the United States, but
Nasacort Aq is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Nasacort Aq's family patents as well as insights into
ongoing legal events
on those patents.
Nasacort Aq's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Nasacort Aq's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jul 03, 2016 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Nasacort Aq Generic API suppliers:
Triamcinolone Acetonide is the generic name for the brand Nasacort Aq. 50 different companies have already filed for the generic of Nasacort Aq, with Astellas having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Nasacort Aq's generic
Alternative Brands for Nasacort Aq
Nasacort Aq which is used for relieving nasal symptoms of seasonal and perennial allergic rhinitis in adults and children two years of age and older., has several other brand drugs using the same active ingredient (Triamcinolone Acetonide). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Bausch And Lomb Inc |
| |
| Chattem Sanofi |
| |
| Harrow Eye |
| |
| Pacira Pharms Inc |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Triamcinolone Acetonide, Nasacort Aq's active ingredient. Check the complete list of approved generic manufacturers for Nasacort Aq
About Nasacort Aq
Nasacort Aq is a drug owned by Sanofi Aventis Us Llc. It is used for relieving nasal symptoms of seasonal and perennial allergic rhinitis in adults and children two years of age and older. Nasacort Aq uses Triamcinolone Acetonide as an active ingredient. Nasacort Aq was launched by Sanofi Aventis Us in 1996.
Approval Date:
Nasacort Aq was approved by FDA for market use on 20 May, 1996.
Active Ingredient:
Nasacort Aq uses Triamcinolone Acetonide as the active ingredient. Check out other Drugs and Companies using Triamcinolone Acetonide ingredient
Treatment:
Nasacort Aq is used for relieving nasal symptoms of seasonal and perennial allergic rhinitis in adults and children two years of age and older.
Dosage:
Nasacort Aq is available in spray, metered form for nasal use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.055MG/SPRAY | SPRAY, METERED | Prescription | NASAL |